An interventional study of Customized porous zirconia shell in Alveolar Bone Loss and Alveolar Ridge Deficiency, sponsored by Mohammed Mahmoud Abed. Recruiting at 1 site in Egypt. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.
Sponsored by Mohammed Mahmoud Abed · Not applicable, Interventional, and Treatment
Among 74 studies in Alveolar Bone Loss with a site in Egypt — 22 open to participants now, 26 under way, none of them phase 3. Alveolar Bone Loss · Egypt.
Among the 74 studies in Alveolar Bone Loss with a site in Egypt, this one is the 64th largest by planned enrollment of the 73 interventional ones that give a count, is one of 14 that started in 2025, is one of 67 with no phase, reaches primary completion later than 23 of the 25 other live ones, and was the 72nd registered.
318 studies on the registry are indexed under Alveolar Bone Loss; 79 are open to participants now.
Browse Alveolar Bone Loss studies →22 of the 74 studies in Alveolar Bone Loss with a site in Egypt are open now. Recruiting first, the newest first:
Horus University · Sites in Egypt
Beni-Suef University · Sites in Egypt
Al Salam University · Sites in Egypt
Future University in Egypt · Sites in Egypt
Basma Gamal Mohamed Ahmed · Sites in Egypt
A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →
Of the 47 Alveolar Bone Loss studies recruiting now, 19 (40%) set no upper age limit and 22 (47%) stop at 75 or younger; 4 take children under 18; 24 take healthy volunteers.
This study: 21 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
74 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 2 · Phase 3 1 · Phase 4 2
First in 2018; this study’s year is marked. 14 started in 2025.
This study's planned enrollment of 10 is below the median of 25 across 269 interventional studies indexed under Alveolar Bone Loss.
Median enrollment 20 across the 73 interventional studies, 23 across the 1 observational. Of the 37 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 74 has an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Mohammed Mahmoud Abed as lead sponsor.
Mohammed Mahmoud Abed has 1 study filed under Alveolar Bone Loss — fewer than ten, so there is no comparison to draw.
6 of the studies in Alveolar Bone Loss with a site in Egypt that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07475507Cairo UniversityEffect of PEEK and Titanium Framework Reinforcement on Marginal Bone Loss Around Implants Supporting a Fixed All-on-four Prosthesis in Completely Edentulous Mandibles | 2026-12 |
| NCT07701473Cairo UniversityNovel Synthetic Membrane for Horizontal Bone Augmentation: A Case Series | 2027-03-01 |
| NCT06313229Kafrelsheikh UniversitySimultaneous Implant Placement With Vertical and Horizontal Bone Augmentation | 2027-04-30 |
| NCT07841158Mohammed Mahmoud AbedHistological and Histomorphometric Assessment With Inflammatory Profile Analysis of Bone Tissue After Horizontal Ridge Augmentation Using Customized Porous Zirconia Shell | 2027-05-01 |
| NCT07869030Future University in EgyptMelatonin Effect on Immediate Dental Implants in the Posterior Mandible | 2027-06 |
Among the 74 studies in Alveolar Bone Loss with a site in Egypt, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical study is to learn whether a custom-made porous zirconia shell can support good-quality new bone when widening the lower back jaw before dental implant placement. The study includes adults whose jawbone in this area is too narrow for implants (Seibert Class I defects).
The main question it aims to answer is: What is the quality of the new bone formed under a porous zirconia shell, and how much inflammation does the tissue show?
Participants will:
Horizontal bone loss in the posterior mandible often prevents dental implant placement. The Khoury technique uses thin autogenous cortical bone plates to rebuild the ridge, but harvesting these plates causes donor-site morbidity, is technically demanding, and is limited by available bone. Zirconia is biocompatible, mechanically strong and osteoconductive, and has shown low inflammatory response. However, it has not been studied as a shell replacing autogenous bone plates.
In this single-arm study, 10 adults with Seibert Class I defects in the posterior mandible will first receive non-surgical periodontal therapy. Compliance will be checked after 1 month. A zirconia shell with 1.5 mm pores will be digitally designed from each patient's CBCT scan, milled on a 5-axis machine, then cleaned and sterilized.
Under local anesthesia, buccal and lingual full-thickness flaps will be raised and the recipient bone decorticated. Autogenous bone chips will be harvested from the mandibular body with a bone chip maker and mixed 1:1 with xenograft. The shell will be fixed over the graft with 3-4 buccal screws. The flaps will be advanced and closed with a double-layer suture.
After 6 months, the shell will be removed, a core biopsy will be taken, and an implant will be placed. The biopsies will be fixed in 10% formalin and analyzed histologically, histomorphometrically and for tissue inflammatory response.
The criteria were revised on the registry on Sep 30, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants with horizontal bone defects in the posterior mandible receive ridge augmentation using a patient-specific porous zirconia shell fixed over a 1:1 mixture of autogenous bone and xenograft. After 6 months, the shell is removed, a bone biopsy is taken, and a dental implant is placed.
Device: Customized porous zirconia shell
A CAD/CAM-milled zirconia shell with 1.5 mm pores, designed from each patient's CBCT scan and fixed with 3-4 buccal screws over a 1:1 mix of autogenous bone chips and xenograft. It replaces the autogenous cortical plates used in the Khoury technique and is removed after 6 months.
Quality of Newly Formed Bone Assessed by Descriptive Histological Analysis of the Core Biopsy
Histological analysis of the core bone biopsy harvested from the augmented site. Specimens will be fixed in a 10% formalin solution. Descriptive analysis of the cells and tissue structure of the augmented site within the biopsy (Dellavia et al., 2021).
Time frame: 6 months after ridge augmentation (at shell removal and implant placement)
Percentage of Newly Formed Bone (% of Total Biopsy Area)
Histomorphometric measurement of the new bone area as a percentage of the total biopsy area.
Time frame: 6 months after augmentation
Percentage of Residual Graft Material (% of Total Biopsy Area)
Histomorphometric measurement of the remaining graft particle area as a percentage of the total biopsy area.
Time frame: 6 months after augmentation
Percentage of Soft Tissue (% of Total Biopsy Area)
Histomorphometric measurement of the non-mineralized connective tissue area as a percentage of the total biopsy area.
Time frame: 6 months after augmentation
Inflammatory Cell Infiltration Score
Semi-quantitative tissue response score from 0 (no inflammatory cells) to 4 (severe cellular infiltrate or tissue necrosis), based on the presence of lymphocytes, macrophages, foreign body giant cells, eosinophils and neutrophils.
Time frame: 6 months after augmentation
Plan to share: No — Individual participant data will not be shared to protect patient confidentiality, as stated in the approved protocol. Study results will be published in a peer-reviewed dental journal.
No publications or documents are linked to this record.
Started Mar 2025 (actual). Primary completion is estimated for May 2027, 25 months after the start.
Of 167 non-industry interventional studies with no phase under Alveolar Bone Loss, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 30. This study's planned 25 months is above that.
Counting every sponsor, half of 167 studies reached it within 18 months; a quarter within 11 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.